Longevity Companies
The biotechs, labs, and AI-driven builders working the aging problem from the inside: cellular reprogramming, senolytics, drug discovery, and longevity biomarkers.
Altos Labs
A heavily-funded private biotech built around cellular reprogramming: resetting a cell's epigenetic age rather than repairing individual symptoms of aging.
BioAge Labs
A clinical-stage biotech that uses AI and large longitudinal human cohort data, rather than animal models alone, to identify longevity drug targets.
Calico
Alphabet's longevity research lab, studying the basic biology of aging with resources and a time horizon most biotechs don't have.
Cambrian Biopharma
A holding company that funds and builds a portfolio of independent longevity biotechs rather than running one research program itself.
Insilico Medicine
A generative-AI drug discovery company that reached human trials with an AI-designed molecule, one of the field's clearest proof points that AI can shorten the path from target to candidate drug.
Life Biosciences
A parent company that spreads its bets across several independent subsidiary programs, each targeting a different aging mechanism, rather than committing to one pathway.
NewLimit
A reprogramming biotech co-founded by Coinbase CEO Brian Armstrong that deliberately narrows its scope to one organ system at a time, starting with the liver.
Retro Biosciences
A Sam Altman-backed biotech targeting the cellular drivers of aging through autophagy, plasma-inspired interventions, and reprogramming, all at once.
Turn Biotechnologies
A reprogramming biotech that uses temporary mRNA delivery instead of DNA-integrating methods, a design choice aimed directly at reprogramming's biggest open safety question.
Unity Biotechnology
A public biotech and one of the first companies to put senolytic drugs, compounds that clear aged, inflammatory cells, into human clinical trials.